You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Improved Esophageal Safety in Atrial Fibrillation Elimination
SBC: Biotex, Inc. Topic: NHLBIThe overall goal of this SBIR proposal is to develop a novel device to allow easier atrial fibrillation (AF) ablation procedures by mitigating risks for esophageal injury. Atrial fibrillation is the most common chronic disease of heart rhythm, and can be treated with application of radiofrequency energy or cryo to ablate susceptible portions of the endocardial surface of the pulmonary veins throug ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Data-Driven Technology Discovery Methodologies
SBC: Semandex Networks Inc. Topic: DTRA162005During the Phase I effort, Semandex Networks and its team developed a prototype capability to detect trends in research publications by automatically identifying emerging concepts within the data. The implemented capability provides insights into past and
SBIR Phase II 2019 Department of DefenseDefense Threat Reduction Agency -
Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction
SBC: VASADE BIOSCIENCES, INC. Topic: NHLBIPROJECT SUMMARY/ABSTRACT The most significant advance in the treatment of Myocardial Infarction (MI) has been reperfusion therapy, which must be applied immediately after the MI diagnosis has been made. Despite the thousands of studies on drug therapies designed to reduce the size of the MI, most have failed in clinical trials. Our hypothesis is that a major reason why these drugs failed is that t ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A user-friendly point-of-care device for G6PDH determination
SBC: ANALYTICAL DIAGNOSTIC SOLUTIONS INC Topic: NIAIDAbstract Malaria caused by Plasmodium vivax threatens over 2 billion people globally and sickens tens of millions annually. Radical cure for P. vivax malaria includes therapy aimed both at the acute attack (blood schizontocidal) and against future attacks (hypnozoitocidal). The only hypnozoitocides available are 8-aminoquinolines such as primaquine or tafenoquine. However, clinicians often do not ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty
SBC: Longeveron LLC Topic: NIAAging Frailty is a biologically driven geriatric syndrome of multisystem physiological decline that is distinct from normal aging and disproportionately increases vulnerability to adverse clinical outcomes. Frailty has an overall prevalence of 10% of those 65 years and older, and there is growing awareness in the geriatric community to diagnose and treat this condition, as it is not an inevitable ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Pediatric Implantable Low-Shear Pulsatile Blood Pump with Physiologic Sensing and Control
SBC: WINDMILL CARDIOVASCULAR Topic: NHLBIProject Summary / Abstract The goal of this project is to develop high-level physiological control, improve low-level dynamic piston control, and develop hemodynamic sensing capabilities for the pediatric TORVADTM, a unique ventricular assist system that delivers low-shear, synchronous, pulsatile flow, using controlled piston motion within a torus-shaped pumping chamber. The pediatric TORVAD is in ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Protein therapeutic to facilitate healing of chronic wounds.
SBC: TRIM-EDICINE INC Topic: 300Project Summary This proposal builds upon the advances from the SBIR-Phase I program (R43GM123887), targeting the development of recombinant human MG53 (rhMG53), a novel tissue repair protein, as a topical therapeutic agent to facilitate healing of chronic wounds. Wound care represents a challenging problem to the public health, as no effective treatments for chronic non-healing wounds are availab ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Cervix monitor for risk assessment of spontaneous preterm delivery
SBC: ADVANCED TACTILE IMAGING INC Topic: NICHDPROJECT SUMMARY Preterm delivery is a leading cause of infant mortality and morbidity. It is estimated that annually about 15 million infants are born preterm. Across 184 countries, the rate of preterm birth ranges from 5% to 18%. In most countries, the rate of preterm birth has risen in the recent decades, and now preterm birth represents the most common cause of neonatal mortality. It is the sec ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Sensitive and Portable Physician Office-Based Urine Analyzer to Tackle Prescription Drug Abuse
SBC: BreviTest Technologies, Inc. Topic: NIDAPROJECT SUMMARY BreviTest Technologies, LLC, proposes to develop a low-cost, point-of-care (POC) urine drug testing (UDT) device to detect opioids. The goal is for the assay platform to deliver quantitative performance similar to a standard laboratory ELISA. Phase I research and development showed the repeatability and accuracy of BreviTest’s proprietary assay technology. Current drug-screening ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of OCF001 for Treatment of Yeast Infections
SBC: Sano Chemicals, Inc. Topic: NIAIDProject Summary Occidiofungins (A-D) are cyclic nonribosomally synthesized antifungal peptides with submicromolar fungicidal activity against a broad spectrum of fungi. Optimization of the production and isolation of occidiofungins from liquid cultures has been performed. The production and isolation of predominantly one analog, called occidiofungin B (OCF001), supports its commercial development ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health